Bullish Case: ABOS trades at $2.79 with market IV peaking near 244% into the Dec-19 expiry, pricing a large positive tail around the late-2026 ALTITUDE-AD readout for sabirnetug. Positive topline or a partner/deal could re-rate shares toward $4-6 from a depressed base, with contango in the wings (Oct 422%/Dec 500% call wing IV) signaling demand for upside convexity.

Bearish Case: Put volume runs 3633% above calls, and put IV (Apr-27 5P ~114%, deep downside wings 200%+) shows the market hedging a failed readout plus dilution. The return surface holds mass at -70% to -84% multi-period returns; the -11.7% week and cash-burn runway risk support a slide toward $1.50-2.20 on a miss.

Potential Outcomes:

1. 25%: Positive ALTITUDE-AD topline/safety → re-rate toward $4-6; falsifiable via topline PR.
2. 28%: Miss/safety issue + financing within ~6mo → $1.50-2.20.
3. 17%: Partner/M&A pre-readout → sharp rerate.
4. 25%: No binary news, rangebound $2.25-3.20 with episodic vol (Sept 16 Investor Day).
5. 5%: Macro/biotech risk-off (SPY vol benign, secondary).

September 15, 2026